Drug repurposing: Landmark achievements in translational medicine

Conflict of interest

Jacek Z. Kubiak is the Editor-in-Chief of this journal, but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. The author declares that he has no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

References

[1] Nosengo N. Can you teach old drugs new tricks? Nature. 2016; 534(7607): 314-316. doi: 10.1038/534314a

[2] Lotfi Shahreza M, Ghadiri N, Mousavi SR, et al. A review of network-based approaches to drug repurposing. Brief Bioinform. 2018; 19(5): 872-891. doi: 10.1093/bib/bbx017

[3] Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019; 18(1): 41-58. doi: 10.1038/nrd.2018.168

[4] Dowling RJO, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012; 48(3): R31-R43. doi: 10.1530/JME-12-0007

[5] Hua Y, Zheng Y, Yao Y, et al. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing. J Transl Med. 2023; 21(1): 403. doi: 10.1186/s12967-023-04263-8

[6] Yu OH, Suissa S. Metformin and cancer: solutions to a real-world evidence failure. Diabetes Care. 2023; 46(5): 904-912. doi: 10.2337/dci22-0047

[7] Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341(21): 1565-1571. doi: 10.1056/NEJM199911183412102

[8] Rajkumar SV. Thalidomide: tragic past and promising future. Mayo Clin Proc. 2004; 79(7): 899-903. doi: 10.4065/79.7.899

[9] Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008; 111(8): 3968-3977. doi: 10.1182/blood-2007-10-117457

[10] Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376(9754): 1741-1750. doi: 10.1016/S0140-6736(10)61543-7

[11] Horby P, Lim WS, Emberson J, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021; 384(8): 693-704. doi: 10.1056/NEJMoa2021436

[12] Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021; 9(12): 1407-1418. doi: 10.1016/S2213-2600(21)00331-3

[13] Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021; 384(9): 795-807. doi: 10.1056/NEJMoa2031994

[14] Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006; 5(8): 689-702. doi: 10.1038/nrd2030

[15] Zhang Z, Huang W, Huang D, et al. Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription. Commun Biol. 2025; 8(1): 724. doi: 10.1038/s42003-025-07519-9

[16] Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006; 2(4): 411-422. doi: 10.2147/vhrm.2006.2.4.411

[17] Rossi A, Cantisani C, Melis L, et al. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012; 6(2): 130-136. doi: 10.2174/187221312800166859

[18] Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. 2022; 33(4): 1896-1906. doi: 10.1080/09546634.2021.1945527

[19] Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens. 2004; 6(5): 283-287. doi: 10.1111/j.1524-6175.2004.03585.x

[20] Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019; 13: 2777-2786. doi: 10.2147/DDDT.S214907

[21] Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020; 6: 14. doi: 10.1038/s41421-020-0153-3